The first GLP-1 agonist pill for Type 2
diabetes has been approved by the
European Medicines Agency (EMA).
Rybelsus (known as oral semaglutide in
clinical trials) is a once-daily tablet version
of Ozempic, a GLP-1 agonist injection,
to be taken alone or in combination with
other treatments for type 2 diabetes.
Rybelsus, manufactured by Novo
Nordisk, was approved in the US in
September 2019. This approval provides
more options for people with Type 2
diabetes - data shows that Rybelsus
lowers blood glucose and improves heart
health, reducing the risk of heart attack,
stroke, and heart-related death. Talk with
your diabetes team for more information.
A health app is helping healthcare
professionals and patients manage
diabetes during pregnancy.
GDm-Health is part of a system that
comprises a patient app that receives
wireless blood glucose readings and
a web-app dashboard for use by
healthcare professionals, where they can
view readings in real-time and proactively
manage their patients' condition.
The system is suitable for women with,
or at risk of, gestational diabetes, or who
are pregnant with pre-existing diabetes.
Healthcare professionals will need
to be using the GDm-Health web-app
dashboard to utilise the full range of
features. This includes uploading and
tracking blood glucose readings, filtering
readings to show trends, requesting
callbacks from the healthcare team,
receiving care guidance directly to the
app and finding out more about living a
Download the app for free from the
App Store or Google Play.
DIGITAL CARE FOR PREGNANCY